Latest Updates
Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) develops, manufactures, and commercializes regenerative biologics and spinal implant systems for surgical procedures and chronic wound care. Based in Belgrade, Montana, the company operates tissue processing facilities that transform human donor tissue and synthetic materials into medical products used primarily in spine surgery and wound care applications.
Xtant recently announced the sale of two non-core businesses, Coflex and the OUS Paradigm Spine operations. The proceeds from the sale will be used to pay down long-term debt, and improve Xtant’s cash position.
Stock Details
Recent News
SEC Filings
Xtant Medical Holdings, Inc. At A Glance
Xtant Medical is a global medical technology company that is executing a strategic transformation to concentrate on its core orthobiologics business. The company develops and commercializes a comprehensive portfolio of regenerative products designed to promote bone and tissue healing in spinal and orthopedic procedures. With a record of strong revenue growth, an established U.S. distribution network, and a pending divestiture intended to streamline operations and improve margins, Xtant is positioning itself as a specialized provider in the multi-billion-dollar spine and biologics markets.
A Strategic Focus on Higher-Margin Orthobiologics
In July 2025, Xtant announced definitive agreements to sell its spinal implant hardware and international businesses. This pending transaction, expected to close in the third quarter of 2025, represents a significant step in the company’s strategy to focus on its core business: the development and commercialization of higher-margin, best-in-class orthobiologics.
Substantial Market Opportunities
Xtant operates within the Regenerative Biologics market which is inclusive of the $2.5B orthobiologics market, and the $12+B advanced woundcare market. The company’s products address the entirety of the $2.5 billion U.S. orthobiologics market, which includes segments such as demineralized bone graft, cellular allograft, and growth factor products.
A Demonstrated Record of Strong Revenue Growth
The company has achieved significant revenue growth, reporting $117.3 million for fiscal year 2024, a 28% increase over the prior year. For fiscal year 2025, Xtant expects revenue of $127 million to $131 million. The company noted its estimated revenue growth for 2025 is expected to be 100% organic.
A Differentiated Biologics Product Portfolio
Xtant's portfolio addresses all five major categories of the U.S. orthobiologics market: Demineralized Bone Graft, Cellular Allograft, Allograft, Synthetic Bone Graft, and Marrow-Derived Growth Factor. With the launch of OsteoFactor Pro™ in May 2025, completing their growth factor offering, Xtant became the first vertically integrated company to provide solutions across all these categories.
An Extensive Distribution Network
Xtant maintains exceptional market access in the United States through its established distribution channels. As of December 31, 2024, the company’s network included over 670 independent sales agents and distributors. Additionally, Xtant holds contracts with 450 Integrated Delivery Networks (IDNs) and major Group Purchasing Organizations (GPOs), including Vizient, Premier, and HealthTrust Purchasing Group.
Vertical Integration Strategy
An increasingly important component of Xtant’s strategy is its transition from lower-margin manufacturing to producing higher-margin biologics in-house. The company has expanded its capabilities to internally produce products that were previously outsourced, such as viable bone matrix and growth factors. This vertical integration is intended to increase product margin, improve profitability, and provide greater control over its supply chain.
OsteoFactor Pro™ is here! Delivering the precision, performance, and progress today’s procedures demand.
📲 DM us or connect with your Xtant rep to get started.
#OsteoFactorPro #XtantMedical #ElevateYourBoneGraft #SpineSurgery #Orthobiologics


Xtant Medical is a global medical technology company that develops, manufactures, and markets biologics and spinal implant systems for orthopedic and neurosurgical specialists. Its vertically integrated platform is distinguished by its inclusion of all five major orthobiologic categories, in addition to amniotic membranes for advanced wound care.
Investment and financial highlights include a “best-in-class” portfolio of orthobiologics that fully covers all five product lines, including demineralized bone graft, cellular allograft, allograft, synthetic bone graft, and marrow-derived growth factor. The company has established exceptional market access through 450 integrated delivery network (IDN) contracts and a network of more than 670 independent distributors.
Xtant Medical operates within a significant addressable market, consisting of a $10.1 billion worldwide spine market and a $2.5 billion U.S. orthobiologics market. A robust R&D pipeline is in place to develop next-generation biologics, with several products launched in 2024 and additional launches scheduled this year and next.
See full press release: https://www.newmediawire.com/news/xtant-medical-partners-with-b2i-digital-to-educate-investors-on-its-orthobiologics-innovation-and-market-opportunity-7081558
The company is led by Chief Executive Officer Sean Browne, Chief Financial Officer Scott Neils, and Chief Operating Officer Mark Schallenberger, whose collective experience spans medical-device commercialization, corporate finance, and orthobiologologic innovation. For more information, visit https://www.xtantmedical.com. Investor inquiries: Kevin Gardner at LifeSciences Advisors, KGardner@lifesciadvisors.com.
Disclosure: The management of B2i Digital may purchase shares of unrestricted XTNT stock in the open market, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the purchase or sale of XTNT
Xtant Medical is a global medical technology company that develops, manufactures, and markets biologics and spinal implant systems for orthopedic and neurosurgical specialists. Its vertically integrated platform is distinguished by its inclusion of all five major orthobiologic categories, in addition to amniotic membranes for advanced wound care.
Investment and financial highlights include a “best-in-class” portfolio of orthobiologics that fully covers all five product lines, including demineralized bone graft, cellular allograft, allograft, synthetic bone graft, and marrow-derived growth factor. The company has established exceptional market access through 450 integrated delivery network (IDN) contracts and a network of more than 670 independent distributors.
Xtant Medical operates within a significant addressable market, consisting of a $10.1 billion worldwide spine market and a $2.5 billion U.S. orthobiologics market. A robust R&D pipeline is in place to develop next-generation biologics, with several products launched in 2024 and additional launches scheduled this year and next.
See full press release: https://lnkd.in/eMN4aQ4h
The company is led by Chief Executive Officer Sean Browne, Chief Financial Officer Scott Neils, and Chief Operating Officer Mark Schallenberger, whose collective experience spans medical-device commercialization, corporate finance, and orthobiologologic innovation. For more information, visit https://lnkd.in/etF3qHWF. Investor inquiries: Kevin Gardner at LifeSciences Advisors, KGardner@lifesciadvisors.com.
Disclosure: The management of B2i Digital may purchase shares of unrestricted XTNT stock in the open market, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the purchase or sale of XTNT or any security, nor does it offer any investment opinion. Conduct your own research and consult professional advisers before making investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/

United States Antimony Corporation (USAC) is a B2i Digital Featured Company. The company’s comprehensive investor profile is at: https://b2idigital.com/united-states-antimony-corp.
Highlights from the company’s announcement include:
- Total mineral reserves of 5.127 million short tons with an average grade of 146.2 CEC (Cation Exchange Capacity).
- Reserve life of more than 400 years at current production rates, or over 20 years if production were scaled up by a factor of 20.
- Property comprises 50 federal placer mining claims (994 acres) plus 320 acres of private leased land.
- Comprehensive drilling program completed with 82 vertical holes totaling 6,713 feet of drilling to validate the reserve base.
To read the full news release, visit: https://www.usantimony.com/_files/ugd/3b68bf_6278db89e7d543988a06361b278ea940.pdf.
USAC produces antimony, zeolite, and precious metals from operations in Montana, Idaho, and Mexico. Antimony products serve flame-retardant, battery, ordnance, and specialty-chemical markets, while Bear River Zeolite supports water filtration, environmental remediation, agriculture, animal nutrition, and other industrial applications.
For investor inquiries, contact Jonathan Miller, VP Investor Relations, at jmiller@usantimony.com.
Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted UAMY stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of UAMY or any security, and it is not intended to offer any opinion on UAMY as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.

United States Antimony Corporation (USAC) is a B2i Digital Featured Company. A comprehensive investor profile will be available soon at https://b2idigital.com/featured-companies.
In the interview, Mr. Evans provided an update on all antimony procurement sourcing being conducted by USAC, both domestically and internationally, for the remainder of fiscal 2025. To watch a replay, visit: https://www.usantimony.com/newsroom. Read the full press release here: https://www.usantimony.com/_files/ugd/3b68bf_26199cc22b4e4bafaf4e0a4b01a71a92.pdf
USAC produces antimony, zeolite, precious metals, cobalt, and tungsten from operations in Montana, Idaho, Mexico, and Canada; its vertically integrated model spans mining, flotation, and smelting. Antimony products serve flame-retardant, battery, ordnance, and specialty-chemical markets, while Bear River Zeolite supports water filtration, environmental remediation, and agriculture.
For investor inquiries, contact Jonathan Miller, VP Investor Relations, at jmiller@usantimony.com.
Disclosure: The management of B2i Digital owns shares of unrestricted UAMY stock, purchased in the open market, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of UAMY or any security, and it is not intended to offer any opinion on UAMY as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.
OsteoFactor™ Pro delivers a naturally derived array of allogenic growth factors to support bone healing and regeneration. Ready to use and compatible with any scaffold, it brings flexibility, efficiency, and biologic performance to the operating room.
#OsteoFactorPro #XtantMedical #Orthobiologics #RegenerativeMedicine
At Xtant Medical, we’re driven by this same belief, every donated gift, every product we create, and every life we help restore is part of something greater.
#HonoringTheGift #XtantMedical #MandelaDay2025

United States Antimony Corporation (USAC) is a B2i Digital Featured Company. https://b2idigital.com/featured-companies
The company noted strong progress in diversifying supply across five countries (Australia, Bolivia, Canada, Chad, and Mexico) while expanding its own U.S. resource base (Alaska, Montana).
Highlights from today’s announcement include:
- A definitive contract in Bolivia will begin shipping 10t of antimony flake in August, ramping toward 150t per month by early 2026 to support the Thompson Falls expansion.
- Two new agreements in Chad will deliver an initial 80t in August, with monthly volumes expected to exceed 100t thereafter for the Madero smelter.
- Canadian supply to Thompson Falls more than doubled year-over-year to 857t in the first half of 2025, building the largest raw-material inventory in USAC’s history.
Commenting on the various sources of antimony outlined in today’s press release, Mr. Gary C. Evans, Chairman & CEO noted, “While management has worked tirelessly all of this year in our efforts to procure new antimony sources of quality raw ore for our two operating smelters, it is evident that there continues to be a worldwide shortage of this critical mineral. Once we sort through the brokers, the traders, the promoters, and finally get to the actual source, we have to then assay the material and determine its ability to be processed. It also has to be in quantities that justify the financial and logistical resources required to actually get the material to our processing facilities. As can be seen by today’s press release, we are making substantial headway with multiple parties and country origins. There are other countries not mentioned here that our management team continues to negotiate with, but we have yet to come to a final agreement. This range of sources substantially reduces our risk as evidenced by our recent issues with the Australian antimony ore. At the same time, we are ramping up our own domestic supply from both Alaska and Montana, which will have substantially higher net margins. These new antimony supplies dovetail nicely with our expansion efforts underway in Thompson Falls, Montana. If our foreign supplies continue increasing as anticipated, we will then consider expanding our smelting capabilities at Madero (currently 200 tons per month) to accommodate this additional increase in anticipated inventory. US Antimony is the only vertically integrated antimony company in the world outside of China. We are confident in our ability to meet the growing demand of our products for both our military and our industrial customers.”
Full Press Release here: https://www.usantimony.com/_files/ugd/3b68bf_8f245f9b0c2741189cba77539cdb2c01.pdf
For investor inquiries, contact Jonathan Miller, VP Investor Relations, at jmiller@usantimony.com.
Disclosure: The management of B2i Digital owns shares of unrestricted UAMY stock, purchased in the open market, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of UAMY or any security, and it is not intended to offer any opinion on UAMY as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclaimer in the Risks and Disclosures section of https://b2idigital.com/disclaimer.
Xtant Medical is hiring, we’re looking for passionate, driven individuals to join our team!
Check out our current openings by scanning the QR code or visiting our careers page. Come be a part of something meaningful!
https://lnkd.in/exFGC6f
#XtantMedical #NowHiring #JoinOurTeam #BelgradeJobs
Important Resources
Including an At-A-Glance PDF, a document tailored to those who just want quick and summarized information.
Xtant Medical Holdings, Inc. management has decades of industry experience.
Xtant Medical Holdings, Inc. management has decades of industry experience. The team specializes in the medical device sector, leveraging extensive knowledge in operations, manufacturing, quality systems, and public company finance to execute the company's growth strategy in the orthobiologics market.
The Xtant Medical Holdings, Inc. executive leadership regularly updates investors with company news. Please fill out this form to receive the latest information.
Note: The company can only disclose information that is shared in the public domain through press releases, SEC filings, and other public forums. As securities law and industry regulations require, such information will always be shared with all investors simultaneously.

